Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL576043 | 0.86 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL5268 | 0.86 | — | — | |
| SCHEMBL28849565 | 0.86 | LMNA (0.47) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL9551494 | 0.84 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Ethane SCHEMBL25228294 | 0.83 | — | — | |
| SCHEMBL20533802 | 0.83 | — | — | |
| SCHEMBL20533540 | 0.83 | — | — | |
| SCHEMBL20533646 | 0.83 | — | — | |
| SCHEMBL22581628 | 0.83 | — | — | |
| SCHEMBL7583398 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781657-A1 | USE OF HYPOPHOSPHOROUS ACID FOR THE ESTERIFICATION OF FREE FATTY ACIDS | ARKEMA FRANCE (FR) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019202276-A1 | USE OF HYPOPHOSPHOROUS ACID FOR THE ESTERIFICATION OF FREE FATTY ACIDS | ARKEMA FRANCE (FR) | 2019-10-24 | — | — | WO | disclosed |
| EP-1991201-B1 | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY | PARI PHARMA GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20090025713-A1 | Nebulised Antibiotics for Inhalation Therapy | PARI PHARMA GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1991201-A1 | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY | PARI Pharma GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007090646-A1 | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY | PARI PHARMA GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2004024140-A1 | EFFLUX PUMP INHIBITORS | ESSENTIAL THERAPEUTICS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-6689782-B2 | 3-PIPERAZINYL-2-DIARYLUREA-QUINAZOLINONE DERIVATIVES; POTENTIATORS OF ANTIFUNGAL AGENTS | ESSENTIAL THERAPEUTICS, INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030229097-A1 | Fungal efflux pump inhibitors | ESSENTIAL THERAPEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030220338-A1 | Fungal efflux pump inhibitors | ESSENTIAL THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6596723-B1 | Compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism. | ESSENTIAL THERAPEUTICS, INC. | 2003-07-22 | — | — | US | disclosed |
| US-6551591-B1 | New antibiotics derived from the cultures of Microbispora corallina and the physicochemical characteristics of those compounds; has units of dehydrobutyrine, dehydroalanine, aminovinylcysteine and tryptophan | ESSENTIAL THERAPEUTICS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-4038225-A | ALKYD RESIN, MELAMINE RESIN, ORGANOSULFONIC ACID, SOLVENT | KANSAI PAINT COMPANY, LTD. (JA) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220338-A1 | Fungal efflux pump inhibitors | ABCB11, ABCB1, ABCC1 | PTGS1 1555/4885PDE4A 2430/4885LMNA 4359/4885 |
| US-20030229097-A1 | Fungal efflux pump inhibitors | ABCB11, ABCB1, ABCC1 | PTGS1 1555/4885PDE4A 2430/4885LMNA 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.